An Open-label, Single Arm Study to Provide Additional Information on Safety and Effectiveness of rVSVΔG-ZEBOV-GP
Phase of Trial: Phase III
Latest Information Update: 27 Nov 2017
At a glance
- Drugs RVSV-S-GP/VP40 vaccine (Primary)
- Indications Ebola virus infections
- Focus Therapeutic Use
- 21 Nov 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
- 25 Jul 2017 Status changed from not yet recruiting to suspended as there are no new cases of Ebola disease.
- 25 Jul 2017 Planned End Date changed from 31 Dec 2017 to 31 Mar 2018.